Skip to main content
PBF logo

PBF — Investor Relations & Filings

Ticker · 1760 ISIN · TW0001760007 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Open in API
Filings indexed 1,562 across all filing types
Latest filing 2022-03-09 Regulatory Filings
Country TW Taiwan
Listing TW 1760

About PBF

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
111年2月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company, providing details about loan balances and guarantee information for the current and previous months, including limits and cumulative amounts. It is a regulatory disclosure related to financial status but does not contain comprehensive financial statements or detailed analysis. The document length is short (613 characters), and it mainly reports specific financial data points without broader context or narrative. This type of document fits best under Regulatory Filings (RNS), as it is a general regulatory announcement of financial information that does not qualify as a full financial report or other specific filing types.
2022-03-09 Chinese
111年2月營業收入
Fund Information / Factsheet Classification · 95% confidence The document is a revenue summary report from a listed company, showing monthly and cumulative net operating revenue figures with comparisons to the prior year. It includes notes on accounting standards (IFRS) and reporting practices. The document is very short (770 characters) and does not contain detailed financial statements or analysis, but rather a brief financial data summary. It is not an annual or interim report, nor an earnings release or management discussion. It is a brief factsheet style summary of key financial data for a period (monthly and year-to-date revenue). Therefore, the best fitting category is Fund Information / Factsheet (FS).
2022-03-09 Chinese
本公司經證交所同意，自111年02月23日起恢復交易
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (1760 寶齡富錦) stating that the stock trading suspension due to material information has ended and trading will resume from 111/02/23. It is a regulatory announcement about trading status, not a financial report or detailed filing. The document length is only 553 characters, indicating it is a brief notice. There is no financial data, no report attached or referenced, and no mention of any specific report type. This fits best under Regulatory Filings (RNS) as a general regulatory announcement about trading status.
2022-02-22 Chinese
本公司腎病新藥拿百磷500毫克膠囊公布中國三期臨床試 驗數據分析結果
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company about the results of a Phase III clinical trial for a new drug, including clinical trial design, statistical results, safety data, and future development plans. It is a regulatory announcement about clinical trial progress and drug development, not a financial report or earnings release. The document is about a specific event (clinical trial data release) and does not contain financial statements or management discussion of financial results. It is not a report publication announcement since it contains substantive data and analysis. The content fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about clinical trial results and company R&D progress, which does not fit other specific categories.
2022-02-22 Chinese
公告本公司今日召開重大訊息說明記者會新聞稿
Regulatory Filings Classification · 95% confidence The document is a press release announcing a significant information briefing held by the company on a specific date. It details clinical trial results for a new drug and provides business and market context. The document is relatively short (2785 characters) and serves as an announcement of information rather than a full financial or management report. It does not contain comprehensive financial statements, management discussion, or regulatory certifications. It is not a transcript, audit report, or any form of detailed financial filing. The content aligns with a Regulatory Filing (RNS) as it is a general regulatory announcement of material information to the market without fitting into more specific categories.
2022-02-22 Chinese
本公司因有重大訊息待公布，經證交所同意自111年02月22日 起暫停交易
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (1760 寶齡富錦) stating that trading will be suspended starting from a specific date due to the pending release of significant information. It includes the date of the event and the approval from the stock exchange for the suspension. The document is only 556 characters long and does not contain any financial data, detailed report, or analysis. It is an official regulatory announcement about trading suspension, which fits best under the category of Regulatory Filings (RNS) as it does not qualify as a full report or other specific filing types.
2022-02-21 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.